Drug Trial Radar · NCT05325866
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
260
Actual
Start
Sep 23, 2022
Primary completion
Jan 28, 2026
Study completion Jan 28, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Apr 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Conditions
- Solid Tumors
Interventions
BemarituzumabDrug
Intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Time frame: Day 1 to Day 28
- Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Day 1 to 28 days after last dose (a maximum of 2 years)
- Part 1: Number of Participants Who Experience a Treatment-related Adverse EventTime frame: Day 1 to 28 days after last dose (a maximum of 2 years)
- Part 2: Objective Response (OR) RateTime frame: Up to approximately 2 years
Locations
115 sites in 26 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
University of California Irvine
Orange, California
Rocky Mountain Cancer Centers
Aurora, Colorado
Community Health Network MD Anderson Cancer Center - North
Indianapolis, Indiana
Henry Ford Hospital
Detroit, Michigan
United States Oncology Regulatory Affairs Corporate Office
Nashville, Tennessee
Texas Oncology - Dallas Fort Worth
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
US Oncology Research Investigational Products Center
Irving, Texas
Texas Oncology Northeast Texas
Tyler, Texas
Centro Oncologico Korben
Buenos Aires, Argentina
Instituto Alexander Fleming
Capital Federal, Buenos Aires, Argentina
Hospital Aleman
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Fundacion Cenit Para La Investigacion
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina
Sociedad de Beneficencia Hospital Italiano
Córdoba, Córdoba Province, Argentina
Fundacion Medica de Rio Negro y Neuquen
Cipolletti, Río Negro Province, Argentina
Liverpool Hospital
Liverpool, New South Wales, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Toowoomba Hospital
Toowoomba, Queensland, Australia
Cabrini Hospital
Malvern, Victoria, Australia
St John of God Murdoch Hospital
Murdoch, Western Australia, Australia
Medizinische Universitaet Graz
Graz, Austria
Landeskrankenhaus Salzburg
Salzburg, Austria
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
Brussels, Belgium
Grand Hopital de Charleroi - Site des Viviers
Charleroi, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, Belgium
Oncoclinicas Rio de Janeiro S A
Rio de Janeiro, Brazil
Hospital das Clinicas da Ufmg
Belo Horizonte, Minas Gerais, Brazil
Centro de Oncologia Mackenzie
Curitiba, Paraná, Brazil
Associacao Hospitalar Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
Instituto do Cancer Arnaldo Vieira de Carvalho
São Paulo, São Paulo, Brazil
Beneficencia Portuguesa de Sao Paulo - Bp
São Paulo, São Paulo, Brazil
Oncologia Rede D Or
São Paulo, São Paulo, Brazil
Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
Plovdiv, Bulgaria
Complex Oncology Center Plovdiv EOOD
Plovdiv, Bulgaria
Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
Sofia, Bulgaria
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.